May 11th 2012 - Edison Investment Research today published a report on Lombard Medical Technologies (LMT.L, LSE:LMT, LON:LMT) entitled "Race Against The Clock". In summary, the report says:
The FDA’s requirement for additional analyses of the existing Aorfix dataset in the PMA process means that the clock on the 180-day review will be restarted once the new data are submitted. It is vital that approval comes before 31 December 2012 for Lombard to receive a £14.2m tranche of funding needed to finance the launch and continue development of the device. If the approval timeline extends further, the company could carry out cost retrenchment or negotiate a new round of funding.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »